Charles Smith, PhD
Research in Dr. Charles Smith's laboratory relates to cancer pharmacology, with a focus on studying the molecular mechanisms of action of established and experimental anticancer drugs, and on designing and developing new drugs against novel molecular targets.
This effort utilizes a multidisciplinary approach that includes biochemical characterization of selected targets for new drugs, synthesis of novel inhibitors of these targets and pharmacological evaluation of the activities of these compounds in both in vitro and in vivo model systems.
The emphasis is currently on studying the roles of sphingolipid metabolizing enzymes, and developing inhibitors of these enzymes.
The Smith lab has synthesized and extensively characterized small molecule inhibitors of sphingosine kinases (SK1 and SK2), which are key regulators of cancer cell proliferation and inflammation. The lab's most-advanced SK2 inhibitor (ABC294640) is currently in multiple clinical trials in cancer patients.
- sphingosine kinase
- Pharmaceutical Preparations
- Multiple Drug Resistance
- Phosphatidylinositol Phosphates
- Protein Kinases